[关键词]
[摘要]
目的 探讨降糖舒胶囊联合利格列汀治疗2型糖尿病的临床效果。方法 选取2017年1月—2019年1月镇平县人民医院收治的2型糖尿病患者106例,随机分成对照组(53例)和治疗组(53例)。对照组患者晨服利格列汀片,5 mg/次,1次/d。治疗组在对照组基础上口服降糖舒胶囊,4粒/次,3次/d。两组患者均连续治疗12周。观察两组患者临床疗效,同时比较治疗前后两组患者糖脂代谢指标空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)和高密度脂蛋白胆固醇(HDL-C),胰岛功能指标李光伟指数(IAI)和胰岛β细胞功能指数(HOMA-β),血流变学指标全血高切黏度(HBV)、全血低切黏度(LBV)、血浆黏度(PV)、红细胞变形指数(EDI)及氧化应激指标超氧化物歧化酶(SOD)、丙二醛(MDA)和SOD/MDA。结果 治疗后,对照组临床有效率83.02%,显著低于治疗组的96.23%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者血清FPG、2 h PG、HbA1c和TG水平均显著降低(P<0.05),但血清HDL-C浓度均显著升高(P<0.05);且治疗后治疗组糖脂代谢参数明显好于对照组(P<0.05)。治疗后,两组患者IAI、HOMA-β值显著升高(P<0.05),且治疗组IAI和HOMA-β值均显著高于对照组(P<0.05)。治疗后,两组患者血流变学指标HBV、LBV、PV、EDI值显著降低(P<0.05),且治疗组比对照组下降更显著(P<0.05)。治疗后,两组患者血清SOD水平和SOD/MDA比值显著上升(P<0.05),而MDA水平显著减少(P<0.05);且治疗组上述氧化应激参数比对照组改善更显著(P<0.05)。结论 降糖舒胶囊联合利格列汀治疗2型糖尿病有助于维持患者血糖稳定,正性调节体内脂代谢紊乱,增强胰岛素敏感性,保护胰岛β细胞功能,抑制机体氧化应激。
[Key word]
[Abstract]
Objective To investigate the clinical effect of Jiangtangshu Capsules combined with linagliptin in treatment of type 2 diabetes mellitus. Methods Patients (106 cases) with type 2 diabetes mellitus in Zhenping County People's Hospital from January 2017 to January 2019 were randomly divided into control (53 cases) and treatment (53 cases) groups. Patients in the control group were po administered with Linagliptin Tablets in the morning, 5 mg/time, once daily. Patients in the treatment group were po administered with Jiangtangshu Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the glucose and lipid metabolism indices of FPG, 2 h PG, HbA1c, TG and HDL-C, islet function indexes of IAI and HOMA-β, hemorheological indexes of HBV, LBV, PV, EDI, and the oxidative stress index levels of SOD、SOD/MDA and MDA in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 83.02%, which was significantly lower than 96.23% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the glucose and lipid metabolism indices of FPG, 2 h PG, HbA1c, TG in two groups were significantly decreased (P<0.05), but the HDL-C levels were significantly increased (P<0.05), and these indices in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the islet function indexes of IAI and HOMA-β in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the hemorheological indexes of HBV, LBV, PV, and EDI in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the oxidative stress index levels of SOD and SOD/MDA in two groups were significantly increased (P<0.05), but the MDA levels were significantly decreased (P<0.05), and these indexes levels in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Jiangtangshu Capsules combined with linagliptin in treatment of type 2 diabetes mellitus is helpful to maintain blood glucose stability, positively regulate lipid metabolism disorders, enhance insulin sensitivity, protect islet β cell function, improve blood rheology, and inhibit oxidative stress.
[中图分类号]
R977
[基金项目]
河南省卫计委科研课题(201605A3086)